These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1725203)

  • 1. Pharmacokinetics of perindopril in high-risk populations.
    Resplandy G; Genissel P
    J Cardiovasc Pharmacol; 1991; 18 Suppl 7():S9-18. PubMed ID: 1725203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.
    Verpooten GA; Genissel PM; Thomas JR; De Broe ME
    Br J Clin Pharmacol; 1991 Aug; 32(2):187-92. PubMed ID: 1657092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure.
    Sennesael J; Ali A; Sweny P; Vandenburg M; Slovic D; Dratwa M; Resplandy G; Genissel P; Desche P
    Br J Clin Pharmacol; 1992 Jan; 33(1):93-9. PubMed ID: 1311597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state.
    Parker E; Aarons L; Rowland M; Resplandy G
    Eur J Pharm Sci; 2005 Sep; 26(1):104-13. PubMed ID: 15982858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of perindopril: therapeutic consequences.
    Lees KR; Hughes DM; McNeill CA; Reid JL
    Clin Exp Hypertens A; 1989; 11 Suppl 2():499-506. PubMed ID: 2605799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of perindopril: therapeutic consequences.
    Lees KR; Hughes DM; McNeill CA; Reid JL
    Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():31-4. PubMed ID: 2505711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of perindopril in patients with liver cirrhosis.
    Thiollet M; Funck-Brentano C; Grangé JD; Midavaine M; Resplandy G; Jaillon P
    Br J Clin Pharmacol; 1992 Mar; 33(3):326-8. PubMed ID: 1576057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis.
    Tsai HH; Lees KR; Howden CW; Reid JL
    Br J Clin Pharmacol; 1989 Jul; 28(1):53-9. PubMed ID: 2550045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum.
    Lecocq B; Funck-Brentano C; Lecocq V; Ferry A; Gardin ME; Devissaguet M; Jaillon P
    Clin Pharmacol Ther; 1990 Mar; 47(3):397-402. PubMed ID: 2311339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perindopril. A review of its pharmacokinetics and clinical pharmacology.
    Macfadyen RJ; Lees KR; Reid JL
    Drugs; 1990; 39 Suppl 1():49-63. PubMed ID: 2407493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinctive properties of perindopril among converting enzyme inhibitors in congestive heart failure.
    Sami MH
    Can J Cardiol; 1994 Nov; 10 Suppl D():13D-16D. PubMed ID: 7954033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril.
    Guérin A; Resplandy G; Marchais S; Taillard F; London G
    Eur J Clin Pharmacol; 1993; 44(2):183-7. PubMed ID: 8453964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.
    Anderson PJ; Critchley JA; Tomlinson B; Resplandy G
    Br J Clin Pharmacol; 1995 Apr; 39(4):361-8. PubMed ID: 7640141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First LC-MS/MS electrospray ionization validated method for the quantification of perindopril and its metabolite perindoprilat in human plasma and its application to bioequivalence study.
    Jain DS; Subbaiah G; Sanyal M; Pande UC; Shrivastav P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jun; 837(1-2):92-100. PubMed ID: 16709467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of perindopril and its metabolites in healthy volunteers.
    Devissaguet JP; Ammoury N; Devissaguet M; Perret L
    Fundam Clin Pharmacol; 1990; 4(2):175-89. PubMed ID: 2351367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients.
    Bellissant E; Giudicelli JF
    Br J Clin Pharmacol; 2001 Jul; 52(1):25-33. PubMed ID: 11453887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects.
    Danielson B; Querin S; LaRochelle P; Sultan E; Mouren M; Bryce T; Stepniewski JP; Lenfant B
    J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S50-9. PubMed ID: 7527102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific and high affinity binding of perindoprilat, but not of perindopril to blood ACE.
    Bree F; Nguyen P; Urien S; Resplandy G; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1992 Sep; 30(9):325-30. PubMed ID: 1330941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perindopril (Coversyl)--a new ACE inhibitor. Perindopril--a review of its pharmacokinetics and clinical pharmacology.
    Reid JL; Macfadyen RJ; Lees KR
    S Afr Med J; 1991 Oct; Suppl():1-5. PubMed ID: 1925812
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacology of perindopril.
    Lees KR
    J Hum Hypertens; 1990 Oct; 4 Suppl 4():7-8; discussion 9-11. PubMed ID: 2283658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.